Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Jan 6:4:1067144.
doi: 10.3389/fmedt.2022.1067144. eCollection 2022.

Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges

Kaushik Pratim Das  1 , Chandra J  1
Affiliations
Review

Nanoparticles and convergence of artificial intelligence for targeted drug delivery for cancer therapy: Current progress and challenges

Kaushik Pratim Das et al. Front Med Technol. .

Abstract

Cancer is a life-threatening disease, resulting in nearly 10 million deaths worldwide. There are various causes of cancer, and the prognostic information varies in each patient because of unique molecular signatures in the human body. However, genetic heterogeneity occurs due to different cancer types and changes in the neoplasms, which complicates the diagnosis and treatment. Targeted drug delivery is considered a pivotal contributor to precision medicine for cancer treatments as this method helps deliver medication to patients by systematically increasing the drug concentration on the targeted body parts. In such cases, nanoparticle-mediated drug delivery and the integration of artificial intelligence (AI) can help bridge the gap and enhance localized drug delivery systems capable of biomarker sensing. Diagnostic assays using nanoparticles (NPs) enable biomarker identification by accumulating in the specific cancer sites and ensuring accurate drug delivery planning. Integrating NPs for cancer targeting and AI can help devise sophisticated systems that further classify cancer types and understand complex disease patterns. Advanced AI algorithms can also help in biomarker detection, predicting different NP interactions of the targeted drug, and evaluating drug efficacy. Considering the advantages of the convergence of NPs and AI for targeted drug delivery, there has been significantly limited research focusing on the specific research theme, with most of the research being proposed on AI and drug discovery. Thus, the study's primary objective is to highlight the recent advances in drug delivery using NPs, and their impact on personalized treatment plans for cancer patients. In addition, a focal point of the study is also to highlight how integrating AI, and NPs can help address some of the existing challenges in drug delivery by conducting a collective survey.

Keywords: artificial intelligence; biomarker; cancer; cancer therapy; drug delivery; nanoparticles.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Nanoparticles for drug delivery. (Reprinted from “Nanoparticle-Mediated Targeted Drug Delivery to Cancer Stem Cells”, by BioRender, June 2020).
Figure 2
Figure 2
Nanoparticle-Mediated targeted drug delivery for cancer treatment. (Reprinted from “Nanoparticle-Mediated Targeted Drug Delivery to Cancer Stem Cells”, by BioRender, June 2020).
Figure 3
Figure 3
Graphical representation of a potential AI-enabled biomarker sensing approach. (Reprinted from “Nanoparticle-Mediated Targeted Drug Delivery to Cancer Stem Cells”, by BioRender, June 2020).
See this image and copyright information in PMC

References

    1. World Health Organization. Cancer. (2022). Available at: https://www.who.int/news-room/fact-sheets/detail/cancer (cited August 29, 2022).
    1. Olusanya TOB, Haj Ahmad RR, Ibegbu DM, Smith JR, Elkordy AA. Liposomal drug delivery systems and anticancer drugs. Molecules. (2018) 23(4):907. 10.3390/molecules23040907 - DOI - PMC - PubMed
    1. De Jong WH, Borm PJ. Drug delivery and nanoparticles: applications and hazards. Int J Nanomedicine. (2008) 3(2):133–49. 10.2147/IJN.S596 - DOI - PMC - PubMed
    1. Kumar A, Sharipov M, Turaev A, Azizov S, Azizov I, Makhado E, et al. Polymer-Based hybrid nanoarchitectures for cancer therapy applications. Polymers (Basel). (2022) 14(15):3027. 10.3390/polym14153027 - DOI - PMC - PubMed
    1. Qindeel M, Sargazi S, Hosseinikhah SM, Rahdar A, Barani M, Thakur VK, et al. Porphyrin-based nanostructures for cancer theranostics: chemistry: fundamentals and recent advances. ChemistrySelect. (2021) 6(48):14082–99. 10.1002/slct.202103418 - DOI